Show simple item record

dc.contributor.authorLøfling, Lukas
dc.contributor.authorStøer, Nathalie Charlotte
dc.contributor.authorNafisi, Sara
dc.contributor.authorUrsin, Giske
dc.contributor.authorHofvind, Solveig Sand-Hanssen
dc.contributor.authorBotteri, Edoardo
dc.date.accessioned2023-08-15T07:44:00Z
dc.date.available2023-08-15T07:44:00Z
dc.date.issued2023-03-06
dc.description.abstractSeveral studies evaluated the association between aspirin use and risk of breast cancer (BC), with inconsistent results. We identifed women aged≥50 years residing in Norway between 2004 and 2018, and linked data from nationwide registries; including the Cancer Registry of Norway, the Norwegian Prescription Database, and national health surveys. We used Cox regression models to estimate the association between low-dose aspirin use and BC risk, overall and by BC characteristics, women’s age and body mass index (BMI), adjusting for sociodemographic factors and use of other medications. We included 1,083,629 women. During a median follow-up of 11.6 years, 257,442 (24%) women used aspirin, and 29,533 (3%) BCs occurred. For current use of aspirin, compared to never use, we found an indication of a reduced risk of oestrogen receptorpositive (ER+) BC (hazard ratio [HR]=0.96, 95% confdence interval [CI]: 0.92–1.00), but not ER-negative BC (HR=1.01, 95%CI: 0.90–1.13). The association with ER+BC was only found in women aged≥65 years (HR=0.95, 95%CI: 0.90–0.99), and became stronger as the duration of use increased (use of≥4 years HR=0.91, 95%CI: 0.85–0.98). BMI was available for 450,080 (42%) women. Current use of aspirin was associated with a reduced risk of ER+BC in women with BMI≥25 (HR=0.91, 95%CI: 0.83–0.99; HR=0.86, 95%CI: 0.75–0.97 for use of≥4 years), but not in women with BMI<25.Use of low-dose aspirin was associated with reduced risk of ER+BC, in particular in women aged≥65 years and overweight women.en_US
dc.identifier.citationLøfling, Støer, Nafisi, Ursin, Hofvind, Botteri. Low-dose aspirin and risk of breast cancer: a Norwegian population-based cohort study of one million women. European Journal of Epidemiology (EJE). 2023en_US
dc.identifier.cristinIDFRIDAID 2134867
dc.identifier.doi10.1007/s10654-023-00976-8
dc.identifier.issn0393-2990
dc.identifier.issn1573-7284
dc.identifier.urihttps://hdl.handle.net/10037/29926
dc.language.isoengen_US
dc.publisherSpringer Natureen_US
dc.relation.journalEuropean Journal of Epidemiology (EJE)
dc.rights.accessRightsopenAccessen_US
dc.rights.holderCopyright 2023 The Author(s)en_US
dc.rights.urihttps://creativecommons.org/licenses/by/4.0en_US
dc.rightsAttribution 4.0 International (CC BY 4.0)en_US
dc.titleLow-dose aspirin and risk of breast cancer: a Norwegian population-based cohort study of one million womenen_US
dc.type.versionpublishedVersionen_US
dc.typeJournal articleen_US
dc.typeTidsskriftartikkelen_US
dc.typePeer revieweden_US


File(s) in this item

Thumbnail

This item appears in the following collection(s)

Show simple item record

Attribution 4.0 International (CC BY 4.0)
Except where otherwise noted, this item's license is described as Attribution 4.0 International (CC BY 4.0)